Journal of Biological Chemistry · 2020 · 33 citations · 78 references
MedicineOncologyPharmacologyCancer PharmacologyCell SignalingSignal TransductionB Cell ActivationB Cell BiologyB Cell PharmacologyHematologic Malignancy TherapyTherapeutic ResistanceTyrosine Kinase InhibitorsBruton Tyrosine KinaseBruton's Tyrosine Kinase InhibitorsBtk InhibitorsChronic Lymphocytic Leukemia TherapyPhospholipase C Gamma 2Primary Resistance FormResistance To Tyrosine Kinase InhibitorsTyrosine Kinase Inhibition
Because catalytically-inactive BTK is insensitive to active-site BTK inhibitors, the mechanism involving the noncatalytic BTK uncovered here may contribute to preexisting reduced sensitivity or even primary resistance of CLL to these drugs.
78
Mobility measurement by analysis of fluorescence photobleaching recovery kinetics
Daniel Axelrod, D E Koppel, Joseph Schlessinger et al. · Biophysical Journal · 1976 · 2.7K citations · Full text
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Klarisa Rikova, Ailan Guo, Qingfu Zeng et al. · Cell · 2007 · 2.3K citations · Full text
Medicine, Cancer Biology, Oncology +16
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu et al. · New England Journal of Medicine · 2014 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +14
A MODIFICATION OF RECEPTOR THEORY
R. P. STEPHENSON · British Journal of Pharmacology and Chemotherapy · 1956 · 1.1K citations · Full text